Tempest Therapeutics, Inc. On September 2, 2023, Tom Dubensky, Ph.D. resigned from his role as president and member of the Board of Directors of Tempest Therapeutics, Inc., and will transition to an advisor role on September 15, 2023. Dr. Dubensky?s resignation was not due to any disagreement with the Company on any matter relating to the Company?s operations, policies, or practices. In connection with Dr. Dubensky?s resignation, the Board will appoint Stephen Brady, the Company?s chief executive officer, as president and chief executive officer effective as of the Separation Date.

Mr. Brady?s responsibilities will remain unchanged.